List of FDA withdrawn drugs,

for hurting People

WRITEN BY LAIMA JONUSIENE MD

To prove that the drug companies make mistakes with our lives we publish this list. Drugs are rushed onto the market for profit. The testing of the drugs is on the major indication. Side effects are NOT tested pre and post. Side effects are observed NOT tested. The expense of pre and post side effect testing is astounding. So it is not done. Side effects are then seen in the public use and a drug is removed from the market after killing or hurting people.

There is a special law that prohibits you from suing a drug company for damages unless you can prove they knew it was harmful and sold it anyway. This means there is even less need to test side effects and or report them during the testing process.

Some drugs have been withdrawn from the market because of risks to the patients. Usually this has been prompted by unexpected adverse effects that were not detected during Phase III clinical

trials and were only apparent from postmarketing surveillance data from the wider patient community.

This list is not limited to drugs that were ever approved by the FDA. Some of them (Lumiracoxib, Rimonabant, Tolrestat, Ximelagatran and Zimelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the U.S., when side effects became clear and their developers pulled them from the market. Likewise LSD was never approved for marketing in the U.S.

Significant withdrawals

Drug name

W i t d Remarks a

n

Thalidomide

1Withdrawn because of risk

5of teratogenicity; sreturned to market for use 1in leprosy and multiple

myeloma under FDA orphan drug rules

1 Lysergic acid diethylamide (LSD)

5Marketed as a psychiatric scure-all; withdrawn after

1it became widely used

6recreationally

Diethylstilbestrol

Phenformin and Buformin

Ticrynafen

Zimelidine

Phenacetin

Methaqualone

s 1Withdrawn because of risk

7of teratogenicity =

sbirth defects 1Withdrawn because of risk

7of lactic acidosis

1 Withdrawn because of risk

8 of hepatitis

Withdrawn

1 worldwide because of risk

8 of Guillain- Barré syndrome An ingredient in "A.P.C." 1 tablet; withdrawn

8 because of risk of cancer and kidney disease

1Withdrawn because of risk

8of addiction and overdose

Nomifensine (Merital) 1Withdrawn because of risk

o

Triazolam

Temafloxacin

Flosequinan (Manoplax)

Alpidem (Ananxyl)

Chlormezanone (Trancopal)

Fen-phen (popular combination of fenfluramine and phentermine)

of hemolytic anemia Withdrawn in the United Kingdom because of risk 1 of psychiatricadve

9 rse drug reactions. This drug continues to be available in the U.S. Withdrawn in the United States because

1of allergic reactions and

9cases of hemolytic anemia, leading to three patient deaths.[1] Withdrawn in the United 1 States because

9 f an increased risk of hospitalization or death

1Withdrawn because of rare

9but serious hepatotoxicity. Withdrawn

1because of rare but serious

9cases of toxic epidermal necrolysis Phentermine

1 remains on the market, 9 dexfenfluramin e and

Tolrestat (Alredase)

Terfenadine (Seldane, Triludan)

Mibefradil (Posicor)

Etretinate

Terodiline (Micturin)

fenfluramine – later withdrawn as caused heart valve disorder

1Withdrawn because of risk

9of severe hepatotoxicity Withdrawn

1because of risk of cardiac

9arrhythmias; superseded by fexofenadine Withdrawn

1because of dangerous

9interactions with other drugs

1 Risk of birth defects; narrow

9 therapeutic

index s 1 Prolonged QT

9interval

Tolcapone (Tasmar)

1

Hepatotoxicity 9

Temazepam (Restoril, Euhypnos, Normison, Remestan, Tenox, Norkotral)

Withdrawn in Sweden and Norway because of

1diversion, abuse, and a

9relatively high rate of overdose deaths in comparison to other drugs of its group. This

Astemizole (Hismanal)

Grepafloxacin (Raxar)

drug continues to be available in most of the world including the U.S., but under strict controls. Arrhythmias

1 because of interactions

9 with other drugs

1 Prolonged QT

9interval

Troglitazone (Rezulin)

Alosetron (Lotronex)

Cisapride (Propulsid)

Amineptine (Survector)

Withdrawn because of risk

2of hepatotoxicity;

0superseded by pioglitazone and rosiglitazone Withdrawn because of risk

2of fatal complications

0of constipation; reintroduced 2002 on a restricted basis

2Withdrawn in many countries

0because of risk of cardiac sarrhythmias Withdrawn

2because of hepatotoxicity,

0dermatological side effects, and abuse potential.

Phenylpropanolamine (Propagest, Dexatrim) 2Withdrawn because of risk

Trovafloxacin (Trovan)

Cerivastatin (Baycol, Lipobay)

Rapacuronium (Raplon)

Rofecoxib (Vioxx)

Co-proxamol (Distalgesic)

mixed amphetamine salts (Adderall XR)

of stroke in women under 50 years of age when taken at high doses (75mg twice daily) for weight loss.

2 Withdrawn because of risk

0 of liver failure

2Withdrawn because of risk

0of rhabdomyolysis Withdrawn in

2 many countries because of risk

0 of fatal bronchospasm

2Withdrawn because of risk

0of myocardial infarction

2Withdrawn in the UK due to

0overdose dangers. Withdrawn in Canada because of risk of stroke. See Health Canada press release.

2The ban was later lifted

0because the death rate among those taking Adderall XR was determined to be no greater than those not

hydromorphone extended-release (Palladone)

Thioridazine (Melleril)

taking Adderall. Withdrawn because of a 2 high risk of accidental 0 overdose when administered with alcohol Withdrawn

2 from U.K. market because

0 of cardiotoxicity Withdrawn

2 from U.S.

Pemoline (Cylert) Natalizumab (Tysabri)

Ximelagatran (Exanta)

Pergolide (Permax)

market because 0 of hepatotoxicity Voluntarily

2withdrawn from U.S. market

0because of risk of Progressive

-multifocal leukoencephalo

0pathy (PML). Returned to

6market July, 2006. Withdrawn

2 because of risk of 0 hepatotoxicity (liver damage). Voluntarily withdrawn in

2the U.S. because of the

0risk of heart valve damage. Still available elsewhere.

Tegaserod (Zelnorm) 2Withdrawn because of

r

Aprotinin (Trasylol)

Inhaled insulin (Exubera)

Lumiracoxib (Prexige)

imbalance of cardiovascular ischemic events, including heart attack and stroke. Was available through a restricted access program until April 2008. Withdrawn because of increased risk

2of complications

0or death; permanently withdrawn in 2008 except for research use Withdrawn in the UK due to poor sales caused by 2 national

0 estrictions on prescribing, doubts over long term safety and too high a cost

2 Progressively

0withdrawn around the

-world because of serious side

0effects, mainly liver damage

8

Rimonabant (Accomplia) 2Withdrawn around the

Efalizumab (Raptiva)

Sibutramine (Reductil)

Gemtuzumabozogamicin (Mylotarg)

Wi th

world because of risk of severe depression and suicide Withdrawn because of increased risk of progressive 2 multifocal leukoencephalo

0 pathy; to be completely withdrawn from market by June 2009 Withdrawn in Europe because

2of increased cardiovascular

1risk. This drug continues to be available in the U.S.

Withdrawn in the U.S. due to increased risks of veno- occlusive

Drug name

Thalidomide

dr aw n

1950s – 1960s

Remarks Withdrawn because of risk of teratogenicity; returned to market for use in leprosy and multiple myeloma under FDA orphan drug rules

disease and based on results of a clinical trial in which it showed no benefit in acute myeloid leukemia (AML)

Lysergic acid diethylamide (LSD)

1950s – 1960s

Marketed as a psychiatric drug; withdrawn after it became widely used recreationally

Diethylstilbestrol 1970s Withdrawn because of risk of teratogenicity

Phenformin and Buformin 1978 Withdrawn because of risk of lactic acidosis

Ticrynafen 1982 Withdrawn because of risk of hepatitis

Zimelidine 1983

Withdrawn worldwide because of risk of Guillain-Barré syndrome

Phenacetin 1983

An ingredient in "A.P.C." tablet; withdrawn because of risk of cancer and kidney disease

Methaqualone 1984 Withdrawn because of risk of addiction and overdose

Nomifensine (Merital) 1986 Withdrawn because of risk of hemolytic anemia

Triazolam 1991

Withdrawn in the United Kingdom because of risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S.

Terodiline (Micturin) 1991 Prolonged QT interval

Temafloxacin 1992

Withdrawn in the United States because of allergic reactions and cases of hemolytic anemia, leading to three patient deaths.[1]

Flosequinan (Manoplax) 1993

Withdrawn in the United States because of an increased risk of hospitalization or death

Not approved in the US, withdrawn in France in 1994[1]

Alpidem (Ananxyl) 1995 and the rest of the market in

1995 because of rare but

serious hepatotoxicity.[2]

Chlormezanone (Trancopal) 1996

Withdrawn because of rare but serious cases of toxic epidermal necrolysis

Fen-phen (popular combination of fenfluramine andphentermine)

1997

Phentermine remains on the market, dexfenfluramine and fenfluramine – later withdrawn as caused heart valve disorder

Tolrestat (Alredase) 1997 Withdrawn because of risk of severe hepatotoxicity

Terfenadine (Seldane, Triludan) 1998

Withdrawn because of risk of cardiac arrhythmias; superseded by fexofenadine

Mibefradil (Posicor) 1998

Withdrawn because of dangerous interactions with other drugs

Etretinate 1990s

Risk of birth defects; narrow therapeutic index

Tolcapone (Tasmar) 1998 Hepatotoxicity

Temazepam (Restoril, Euhypnos, Normison, Remestan, Tenox, Norkotral)

1999

Withdrawn in Sweden and Norway because of diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group. This drug continues to be available in most of the world including the U.S., but under strict controls.

Astemizole (Hismanal) 1999 Arrhythmias because of interactions with other drugs

Grepafloxacin (Raxar) 1999 Prolonged QT interval

Levamisole (Ergamisol) 1999

Still used as veterinary drug; in humans was used to treat melanoma before it was withdrawn for agranulocytosis

Troglitazone (Rezulin) 2000

Withdrawn because of risk of hepatotoxicity; superseded by pioglitazone and rosiglitazone

Alosetron (Lotronex) 2000

Withdrawn because of risk of fatal complications of constipation; reintroduced 2002 on a restricted basis

Cisapride (Propulsid) 2000s

Withdrawn in many countries because of risk of cardiac arrhythmias

Amineptine (Survector) 2000

Withdrawn because of hepatotoxicity, dermatological side effects, and abuse potential.

Phenylpropanolamine (Propagest , Dexatrim)

2000

Withdrawn because of risk of stroke in women under 50 years of age when taken at high doses (75 mg twice daily) for weight loss.

Trovafloxacin (Trovan) 2001 Withdrawn because of risk of liver failure

Cerivastatin (Baycol, Lipobay) 2001 Withdrawn because of risk of rhabdomyolysis

Rapacuronium (Raplon) 2001

Withdrawn in many countries because of risk of fatal bronchospasm

Nefazodone 2003

Branded version withdrawn by originator in several countries in 2003, and in the US and Canada in 2004 for hepatotoxicity. Generic versions available.

Rofecoxib (Vioxx) 2004 Withdrawn because of risk of myocardial infarction

Co-proxamol (Distalgesic) 2004 Withdrawn in the UK due to overdose dangers.

mixed amphetamine salts (Adderall XR)

2005

Withdrawn in Canada because of risk of stroke. See Health Canada press release. The ban was later lifted because the death rate among those taking Adderall XR was determined to be no greater than those not taking Adderall.

hydromorphone extended-release (Palladone)

2005

Withdrawn because of a high risk of accidental overdose when administered with alcohol

Valdecoxib (Bextra) 2005

Withdrawn in US due to concerns about heart attack and stroke.

Thioridazine (Melleril) 2005 Withdrawn from U.K. market because of cardiotoxicity

Pemoline (Cylert) 2005 Withdrawn from U.S. market because of hepatotoxicity

Natalizumab (Tysabri)

2005– 2006

Voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July, 2006.

Ximelagatran (Exanta) 2006 Withdrawn because of risk of hepatotoxicity (liver damage).

Pergolide (Permax) 2007

Voluntarily withdrawn in the U.S. because of the risk of heart valve damage. Still available elsewhere.

Tegaserod (Zelnorm) 2007

Withdrawn because of imbalance of cardiovascular ischemic events, including heart attack and stroke. Was available through a restricted access program until April 2008.

Aprotinin (Trasylol) 2007

Withdrawn because of increased risk of complications or death; permanently withdrawn in 2008 except for research use

Inhaled insulin (Exubera) 2007

Withdrawn in the UK due to poor sales caused by national restrictions on prescribing, doubts over long term safety and too high a cost

Lumiracoxib (Prexige)

2007– 2008

Progressively withdrawn around the world because of serious side effects, mainly liver damage

Rimonabant (Acomplia) 2008

Withdrawn around the world because of risk of severe depression and suicide

Efalizumab (Raptiva) 2009

Withdrawn because of increased risk of progressive multifocal leukoencephalopathy

Sibutramine (Reductil/Meridia) 2010

Withdrawn in Europe, Australasia, Canada, and the U.S. because of increased cardiovascular risk

Gemtuzumabozogamicin (Mylotar g)

2010

Withdrawn in the U.S. due to increased risks of veno- occlusive disease and based on results of a clinical trial in which it showed no benefit in acute myeloid leukemia (AML)

Propoxyphene (Darvocet/Darvon) 2010

Withdrawn from worldwide market because of increased risk of heart attacks and stroke.[3]

Rosiglitazone (Avandia) 2010

Withdrawn in Europe because of increased risk of heart attacks and death. This drug continues to be available in the U.S.

Drotrecoginalfa (Xigris) 2011

Withdrawn by Lily worldwide following results of the PROWESS-SHOCK study that showed lack of efficacy.

Examples of adverse effects associated with specific medications[edit]

Condition Substance

Abortion, miscarriage or uterine he morrhage

misoprostol, a labor-inducing drug (this is a case where the adverse effect has been used legally and illegally for performing abortions)

Addiction many sedatives and analgesics such as diazepam, morphine, etc.

Birth defects thalidomide and isotretinoin

Bleeding of the intestine aspirin therapy

Cardiovascular disease COX-2 inhibitors (i.e. rofecoxib)

Deafness and kidney failure gentamicin (an antibiotic)

Death, following sedation propofol

Depression or hepatic injury interferon

Depression tetrabenazine, rimonabant and other CB1 antagonists

Diarrhea orlistat

Erectile dysfunction many drugs, such as antidepressants

Fever

vaccination (in the past, imperfectly manufactured vaccines, such as BCG and poliomyelitis, have caused the very disease they intended to fight).

Flatulence acarbose

Glaucoma corticosteroid-based eye drops

Hair loss and anemia chemotherapy against cancer, leukemia, etc.

Headache spinal anesthesia

Hypertension ephedrine users, which prompted FDA to remove the status of dietary supplement of ephedra extracts

Impaired glucose tolerance and diabetes

atypical antipsychotic medications, such as clozapine and olanzapine

Insomnia stimulants (e.g. methylphenidate, amphetamine, etc.)

Kidney stones indinavir, carbonic anhydrase inhibitors (such as topiramate)

Lactic acidosis stavudine (an antiretroviral drug) or metformin (oral anti-diabetic medication)

Liver failure paracetamol

Melasma and thrombosis estrogen-containing hormonal contraception such as the combined oral contraceptive pill

Pathological addiction, like gambling, shopping; sexual and other intense urges

dopamine agonists

Irreversible Peripheral neuropathy fluoroquinolone medications [21][22][23]

Rhabdomyolysis statins (a class of lipid-lowering drugs)

Seizures withdrawal from benzodiazepines

Stroke or heart attack sildenafil when used with nitroglycerine; COX-2 inhibitors

Suicide, increased tendency antidepressants

Parkinsonism MPTP, a meperidine related drug considered highly neurotoxic

Tardive dyskinesia long-term use of metoclopramide, cinnarizine and many antipsychotic medications

Spontaneous Tendon rupture fluoroquinolone drugs [24] even occurring as late as 6 months after treatment had been terminated.[25]�

Weight loss some antidepressants, like fluoxetine and bupropion

Weight gain some antipsychotics (e.g. olanzapine and clozapine) and antidepressants (mirtazapine)

October 01, 2013 Hospira Recalls One Lot of Metoclopramide Injection, USP, and two lots of Ondansetron Injection, USP, Due to Glass (Glass Strands) Particulates

September 13, 2013 Hospira Recalls One Lot of 0.25% Bupivacaine HCL Injection, USP (2.5 MG/ML), 30 ML Single-Dose Vial and One Lot of 0.75% Bupivacaine HCL Injection, USP (7.5 MG/ML), 30 ML Single Dose Vial

September 10, 2013 Leiter's Compounding Pharmacy Recalls Three Product Lots Due to Lack of Assurance of Sterility Concerns Related to its Independent Testing Vendor

September 10, 2013 Park Compounding: Sterile Medication Recall – Concerns of Sterility

Assurance at Testing Vendor

September 09, 2013 Avella Specialty Pharmacy Issues Voluntary Nationwide Recall of Two Medications Due to Concerns of Sterility Assurance at Testing Vendor

September 06, 2013 McNeil Consumer Healthcare Announces Voluntary Recall of Three Lots of Concentrated MOTRIN Infants Drops Original Berry Flavor 1/2 fl oz.

September 06, 2013 University Compounding Pharmacy Initiates a Nationwide Voluntary Recall of Certain Pharmacy Products due to Lack of Assurance of Sterility Concerns

September 06, 2013 Altaire Pharmaceuticals, Inc. Recalls 9 Lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution Sold Under Several Brands

September 04, 2013 Medaus Pharmacy Initiates a Nationwide Recall of Certain Pharmacy Products due to Questions Surrounding an Independent Third Party’s Sterility Testing

August 29, 2013 Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Four Lots of Cubicin (Daptomycin for Injection) 500mg in 10ml Single Use Vials Due to Presence of Particulate Matter

August 27, 2013 JCB Laboratories Issues Voluntary Recall of Six Drug Product Lots Due to Concerns of Sterility Assurance at Testing Vendor

August 26, 2013 Wellness Pharmacy, Inc. Issues Voluntary Recall of Six Medications Due to Concerns of Sterility Assurance at Testing Vendor

August 23, 2013 Park Pharmacy & Compounding Center is Issuing a Voluntary Recall of Two Compounded Sterile Preparations. The Recall is Due to a Lack of Sterility Assurance

August 17, 2013 Aidapak Services Llc Initiates Voluntary Recall of Selected Pharmaceuticals Repackaged by Aidapak Services Llc Due to Potential Incorrect Labeling Aidapak Shipped Affected Products to Four States Only: Washington, Oregon, California, and Arizona

August 09, 2013 Specialty Compounding, LLC Issues Nationwide Voluntary Recall of All Lots of Unexpired Sterile Products Due to Reports of Adverse Events

August 01, 2013 Nexus Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of BenztropineMesylate Injection, USP 2 mg/2 mL (1 mg/mL), in 2 mL Single Dose Vials

July 31, 2013 Beacon Hill Pharmacy d/b/a Rxtra Solutions Issues Voluntary Nationwide Recall of Certain Sterile Products Due to a Question of Sterility Assurance

July 03, 2013 Sandoz US Announces Voluntary Nationwide Recall of One Lot of Estarylla

June 30, 2013 Fresenius Kabi USA Issues Voluntary Nationwide Recall of BenztropineMesylate Injection, USP 2 mg/2 mL (1 mg/mL), in 2 mL Single Dose Vials

June 19, 2013 Advance Pharmaceutical Inc. Issues Voluntary Recall of One Lot of Enteric Coated Aspirin Tablets, 81 mg, Due to Health Risk

June 13, 2013 Sagent Pharmaceuticals Expands a Nationwide Voluntary Recall to All Lots of Vecuronium Bromide for Injection, 10mg Single Use Vials Manufactured by Mustafa Nevzat (MN Pharmaceuticals)

June 10, 2013 Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets

June 07, 2013 Sagent Pharmaceuticals Recalls Three Lots of Vecuronium Bromide for Injection, 10mg Manufactured by Mustafa Nevzat (MN Pharmaceuticals) Due to Elevated Impurity Levels

May 29, 2013 Lowlite Investments, Inc. d/b/a Olympia Pharmacy Announces a Voluntary Multi-State Recall of All Sterile Compounded Products Compounded Between December 17, 2012, and March 27, 2013, Due to Concerns About Sterility Assurance

May 28, 2013 Main Street Family Pharmacy, LLC Issues Voluntary Nationwide Recall of All Sterile Compounded Products

May 25, 2013 Fresenius Kabi USA Initiates Voluntary Recall of Single Lot of Magnesium Sulfate

May 20, 2013 Sandoz US Announces Voluntary Nationwide Recall of two lots of Methotrexate Sodium, USP, Injectable Vials, 25mg/mL, 40mL vials

May 15, 2013 Pentec Health Announces Limited Voluntary Recall of Certain Compounded Prescription Therapies for Renal Patients

May 06, 2013 In Cooperation with FDA, The Compounding Shop, LLC Declares a Voluntary Recall of All Lots of Sterile Compounded Products Due to a Lack of Sterility Assurance Distributed Within its Local Market Area

May 10, 2013 Additional Lots Added: Voluntary Nationwide Recall of 21 Lots of Piperacillin and Tazobactam for Injection, USP 40.5 Grams Due to Possibility of Precipitation / Crystallization in IV Bag or IV Line Upon Reconstitution

April 26, 2013 Voluntary Nationwide Recall of 15 Lots of Piperacillin and Tazobactam for Injection, USP 40.5 Grams Due to Possibility of Precipitation / Crystallization in IV Bag or IV Line Upon Reconstitution

April 26, 2013 Hospira Issues a Voluntary Nationwide Recall of One Lot Of 0.9% Sodium Chloride Injection, Usp, 100 Ml, Flexible Containers Due to Particulate – Revised to Update Stericycle Phone Number

April 22, 2013 Nora Apothecary & Alternative Therapies Announces a Voluntary Multi-State Recall of All Sterile Compounded Products Due to a Lack of Sterility Assurance

April 17, 2013 Balanced Solutions Compounding Pharmacy, LLC. Recalls All Sterile Compounded Products Due to a Lack of Sterility Assurance

April 15, 2013 ApothéCure, Inc. Recalls All Lots of All Sterile Products Compounded, Repackaged, and Distributed by ApothéCure, Inc. Due to Sterility Assurance Concerns

April 15, 2013 NuVision Pharmacy Recalls All Lots of All Lyophilized Products Compounded by NuVision Pharmacy Due to Sterility Assurance Concerns

April 05, 2013 Green Valley Drugs Recalls All Lots of All Sterile Products Compounded, Repackaged, and Distributed by Green Valley Drugs Due to Quality Control Concerns

March 29, 2013 Hospira Recalls One Lot of 0.9% Sodium Chloride Injection Due to Brass Particulates

March 26, 2013 Pallimed Solutions, Inc. Announces Voluntary Nationwide Recall of All Sterile Compounded Products Dispensed

March 20, 2013 Medprep Consulting Inc. Announces Voluntary Nationwide Recall Of All Lots Of All Compounded Products Due To Potential Mold Contamination

March 20, 2013 Clinical Specialties Compounding Pharmacy Recalls All lots of Sterile Products Repackaged and Distributed by Clinical Specialties Compounding Due to Lack of Sterility Assurance

March 18, 2013 Clinical Specialties Issues Voluntary Nationwide Recall of Avastin Unit Dose Syringes due to Potential Serious Eye Infection

March 17, 2013 Medprep Consulting Inc. Announces Voluntary Nationwide Recall Of All Lots Of All Compounded Products Due To Potential Mold Contamination

March 16, 2013 Medprep Consulting Inc. Recalls All Lots Of Magnesium Sulfate 2gm In Dextrose 5 percent In Water, 50ml For Injecton Due To Mold Contamination

February 23, 2013 Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection

February 15, 2013 Reumofan Plus USA, LLC and Reumofan USA, LLC is Voluntarily Recalling all lots of Reumofan Plus Tablets Due to Undeclared Drug Ingredients

February 15, 2013 Gilead Recalls One Lot of Vistide® (CIDOFOVIR INJECTION) Due To Presence Of Particulate Matter

January 17, 2013 Advance Pharmaceutical Recalls one Lot (# 12G468) of Ferrous Sulfate Tablets, 325 mg, that may actually contain Meclizine HCl 25 mg tablets

January 10, 2013 Mobius Therapeutics, LLC Issues a Voluntary Recall of Mitosol® (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use

COUNTERTHlNK "rDVlS\ON TEST"

QO '\ f\ \ &,

'OOC.

co FLICTS OF INTEREST CON

'PLICTS OF INTEREST COllFLtCT!I OP 1N't £ST c.oMJ\.•''n OJ ....t '\' CAM,:\.t..""n 011 "'' "(\

•,<

·...

FDA employees ar·e tr·ained in SINthetic dr·ugs, and hope to get better· paying jobs, gr·ants, tr·ips, favor·s to relatives and fr·iends by Dr·ug companies. They are unable to see the damages of evidence based SINthetic dr·ugs

COUHTERiHINK

!I titne !JC>f\e

first ruMished. Yes the ·Dru!J CC>"'f'at'lies al'\d the fDA are sittif\!1 C>f\ the researth that C>f\fittns C>l'\d a shade>w c,f dC>ut that the S l'thetidru!JS

Mt safe af\d the dC> 11\C>te ham thai\ !JC>C>d. Sut sif\e rnedidl'e has e C>tne SC> deref\del't C>f\ these

dru!JS, the dtu!l C>tnf'ar.ies hne SC>C>C>C> tnuh 11\C>l'\e, we>uld e diffi ult tC> reteah all dC> tC>rs rnedidf\e,

the fDA af\d ·Dru!JS sit C>Y.' the researth , af\d dtu!l

aused iatre>!lef\idisease iHreases Drarnati aH

The origins of Synthetic Phannaceuticals came from doctors like Fleming and other doctors who thought that drug companies should not be built on Profit but on serving People at the lowest price possible. But these English ideas turned to Profit based ideas as the drug companies took hold in America. These ruthless corporations are

ruled by Profit and Profit alone. And Greed Rules over all.

This list is from 1999. The following drug products were withdrawn or removed from the market because such drug products or components of such drug products were found to be unsafe or not effective. The following drug products may not be compounded under the exemptions provided by section 503A(a) of the Federal Food, Drug, and Cosmetic Act:

Adenosine phosphate: All drug products containing adenosine phosphate.

Adrenal cortex: All drug products containing adrenal cortex. Azaribine: All drug products containing azaribine. Benoxaprofen: All drug products containing benoxaprofen. Bithionol: All drug products containing bithionol. Bromfenac sodium: All drug products containing bromfenac sodium. Butamben: All parenteral drug products containing butamben.

Camphorated oil: All drug products containing camphorated oil. Carbetapentane citrate: All oral gel drug products containing carbetapentane citrate.

Casein, iodinated: All drug products containing iodinated casein. Chlorhexidinegluconate: All tinctures of chlorhexidine gluconate formulated for use as a patient preoperative skin preparation. Chlormadinone acetate: All drug products containing chlormadinone acetate.

Chloroform: All drug products containing chloroform. Cobalt: All drug products containing cobalt salts (except

radioactive forms of cobalt and its salts and cobalamin and its

derivatives). Dexfenfluramine hydrochloride: All drug products containing

dexfenfluramine hydrochloride. Diamthazoledihydrochloride: All drug products containing diamthazoledihydrochloride. Dibromsalan: All drug products containing dibromsalan.

Diethylstilbestrol: All oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose. Dihydrostreptomycin sulfate: All drug products containing dihydrostreptomycin sulfate. Dipyrone: All drug products containing dipyrone. Encainide hydrochloride: All drug products containing encainide hydrochloride. Fenfluramine hydrochloride: All drug products containing fenfluramine hydrochloride. Flosequinan: All drug products containing flosequinan.

Gelatin: All intravenous drug products containing gelatin. Glycerol, iodinated: All drug products containing iodinated

glycerol. Gonadotropin, chorionic: All drug products containing chorionic

gonadotropins of animal origin. Mepazine: All drug products containing mepazine hydrochloride or mepazine acetate. Metabromsalan: All drug products containing metabromsalan.

Methamphetamine hydrochloride: All parenteral drug products containing methamphetamine hydrochloride. Methapyrilene: All drug products containing methapyrilene. Methopholine: All drug products containing methopholine. Mibefradildihydrochloride: All drug products containing mibefradildihydrochloride.

Neomycin sulfate: All parenteral drug products containing neomycin sulfate. Nitrofurazone: All drug products containing nitrofurazone (except topical drug products formulated for dermatalogic application). Nomifensine maleate: All drug products containing nomifensine maleate. Oxyphenisatin: All drug products containing oxyphenisatin. Oxyphenisatin acetate: All drug products containing oxyphenisatin acetate. Phenacetin: All drug products containing phenacetin. Phenformin hydrochloride: All drug products containing phenformin hydrochloride. Pipamazine: All drug products containing pipamazine.

Potassium arsenite: All drug products containing potassium arsenite.

Potassium chloride: All solid oral dosage form drug products containing potassium chloride that supply 100 milligrams or more of potassium per dosage unit (except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion). Povidone: All intravenous drug products containing povidone.

Reserpine: All oral dosage form drug products containing more than 1 milligram of reserpine. Sparteine sulfate: All drug products containing sparteine sulfate. Sulfadimethoxine: All drug products containing sulfadimethoxine.

Sulfathiazole: All drug products containing sulfathiazole (except those formulated for vaginal use). Suprofen: All drug products containing suprofen (except ophthalmic solutions).

Sweet spirits of nitre: All drug products containing sweet spirits of nitre. Temafloxacin hydrochloride: All drug products containing temafloxacin hydrochloride. Terfenadine: All drug products containing terfenadine.

3,3',4',5-tetrachlorosalicylanilide: All drug products containing 3,3',4',5-tetrachlorosalicylanilide.

Tetracycline: All liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 milligrams/milliliter. Ticrynafen: All drug products containing ticrynafen. Tribromsalan: All drug products containing tribromsalan. Trichloroethane: All aerosol drug products intended for inhalation containing trichloroethane.

Urethane: All drug products containing urethane. Vinyl chloride: All aerosol drug products containing vinyl

chloride. Zirconium: All aerosol drug products containing zirconium.

Zomepirac sodium: All drug products containing zomepirac sodium.

Dated: October 1, 1998.

THE SPECIAL LAW FOR THE PHARMECEUTCAL COMPANIES

In the real world of commerce, if a company sells you something that hurts somebody you can sue them for damages. The Toyota cars killed people, and they had to pay damages. But the drug companies have a special exemption to this liability. To sue them for damages you must prove they knew it would hurt before they sold it and sold it anyway. Just being hurt is not enough to get damages. You must prove that they knowingly sold a drug that could hurt.

This allows them to hurt people and make massive profits and not be held responsible for damages. But still they are sued for damages in the multi billions of dollars each year when lawyers feel they have a case and can possibly prove the company knowingly sold a harmful substance.

If we change this law and hold them responsible for all damages then the world changes.